AngioDynamics, Inc. Q1 2027 Earnings Call Summary Moby Intelligence Thu, October 8, 2026 at 12:55 PM EDT 4 min read NVDA -2.43% ANGO -19.03% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
The company is successfully executing a multi-year transformation, with the MedTech segment now representing 49% of total revenue and growing 13.2% year-over-year.
Auryon achieved its 21st consecutive quarter of double-digit growth, driven by a strategic shift toward hospital settings while maintaining strong performance in office-based laboratories.
Mechanical thrombectomy growth is attributed to product versatility and commercial team execution, allowing the company to capture market share from competitors despite a tough year-over-year comparison for AngioVac.
NanoKnife is transitioning into a primary tool for prostate care, with record procedure volumes and significant capital sales growth signaling increased physician adoption.
The MedDevice segment grew 1.4%, serving its strategic role as a steady cash flow generator to fund high-growth MedTech platform investments.
Gross margin expansion of 410 basis points was primarily driven by favorable pricing and the ongoing revenue mix shift toward higher-margin MedTech products.
Management announced the appointment of Eric Honer as the new President and CEO, effective November 2, following a comprehensive search for Jim Clemmer's successor.
Full-year revenue guidance of $336 million to $341 million assumes MedTech growth of 12% to 15% and flat performance in the MedDevice segment.
Management expects the MedTech segment to comprise the majority of total company revenue during the current fiscal year.
Future growth is dependent on clinical milestones, including the AlphaReturn blood management system IDE trial and the AMBITION BTK study for Auryon.
The company is targeting consistent nationwide reimbursement for NanoKnife by working with additional regional Medicare Administrative Contractors following recent positive coverage decisions.
Fiscal 2027 gross margin guidance of 54% to 55% accounts for a manufacturing transition and global inflation, with higher margins expected in the first half of the year.
Gross margins benefited from $1.2 million in tariff refunds during the quarter; excluding this, the adjusted gross margin was 57.8%.
The company received FDA approval for the RELIEF study, evaluating NanoKnife for BPH, representing a potential $1.9 billion market opportunity.
Management noted that capital sales for NanoKnife are inherently 'lumpy' and the high growth rate seen this quarter is not expected to be sustained consistently.
The company remains debt-free and expects to generate positive cash flow from operations for the full fiscal year despite typical high cash usage in Q1.
Management views disposable sales as the true bellwether for the business, noting that record procedure volumes were achieved in Q1.
Capital placements are facilitated through various models to ensure urologists have access without capital being a 'governor' on adoption.
One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.
Growth is being driven by recent commercial organization changes and physician enthusiasm for product versatility in pulmonary embolism (PE) cases.
The AlphaReturn project is expected to reach 'on label' status in early calendar year 2027, removing a key market hurdle.
Management clarified that Q1 typically sees a sequential dip from Q4 due to med-device seasonality, but underlying procedure volumes actually increased sequentially.
Q3 is structurally the softest quarter due to the December-February timeframe.
Underlying margin trajectory is strong due to price increases in the MedDevice segment and the mix shift toward MedTech.
Cost savings from the Costa Rica manufacturing transition are already being realized and are factored into the current baseline.
The RELIEF study is an early-stage pilot to understand tissue impact and build a business case for BPH as a long-term platform opportunity.
Future R&D spending is expected to remain around 10% of sales, which management believes is sufficient to fund these platform expansions.
